The National Psoriasis Foundation and Amgen (NASDAQ: AMGN), has announced survey findings which show that nearly 40 percent of 1,142 patients surveyed with chronic moderate or severe psoriasis are not currently receiving any treatment. These results were presented at the American Academy of Dermatology (AAD) Scientific Meeting in Washington, D.C.

According to AAD therapy guidelines, patients diagnosed with chronic moderate to severe plaque psoriasis are candidates for phototherapy or systemic therapy, including biologic agents. Despite the increased number of psoriasis treatment options, the findings show no significant change in treatment patterns across three survey years.

According to further data presented at AAD, based on National Psoriasis Foundation surveys from 2003 to 2005, more than half of moderate to severe patients on treatment are not being treated as recommended by AAD guidelines. Of those treated, 57 percent of patients with severe psoriasis (n=459) and 73 percent of patients with moderate psoriasis (n=683) are receiving topical treatment alone.

"Psoriasis is not a cosmetic disease, but rather a chronic inflammatory condition that can have a profound negative impact on a person's ability to function," said Mark Lebwohl, M.D., Chairman of the National Psoriasis Foundation Medical Board. "It's important for patients to openly discuss with their dermatologist how the condition may be impacting them, so that together they can determine the most appropriate treatment option."

According to additional survey findings, severe psoriasis is associated with lower income. Data presented at AAD show that 21 percent of patients with severe psoriasis (n=179) had a low household income (<$30,000), compared to 13 percent for patients with mild psoriasis (n=180).

"These are the first data to show a relationship between psoriasis severity and household income," said Liz Horn, Ph.D., director of research, National Psoriasis Foundation. "Psoriasis is a serious disease that can significantly impact a patient's life by interfering with everyday activities, including work. Further research will be valuable in supporting these data and will hopefully lead to the improved treatment of psoriasis."

Data from semi-annual patient surveys conducted by the National Psoriasis Foundation from 2003 to 2005 were combined and analyzed to study treatment patterns for psoriasis patients. Psoriasis severity was assessed using patient-reported affected body surface area (BSA) and was defined as mild (<3% BSA), moderate (3-10% BSA), or severe (>10% BSA). A separate analysis was conducted in patients greater than 30 years of age to study the relationship between psoriasis severity and household income. The research was funded by the National Psoriasis Foundation, Amgen Inc. and Wyeth Pharmaceuticals.

###

About Psoriasis

Psoriasis is a non-contagious, chronic disease, in which the immune system causes the skin to grow at an accelerated rate. According to the National Institutes of Health, up to 7.5 million people in the United States suffer from psoriasis. The disease occurs among people of all ages, although it is most commonly diagnosed in early adulthood. Types of psoriasis include plaque, guttate, pustular, inverse, and erythrodermic. Due to genetic factors, certain people are more likely to develop psoriasis, but a "trigger" is usually necessary to make psoriasis appear. These triggers may include emotional stress, injury to the skin, some types of infection, or reaction to certain drugs.

About the National Psoriasis Foundation

The National Psoriasis Foundation is the leading patient-driven, nonprofit organization dedicated to improving the quality of life millions of Americans with psoriasis and/or psoriatic arthritis, and their families. The Psoriasis Foundation focuses on education, advocacy and research toward better treatments and a cure. For more information, please call the National Psoriasis Foundation, headquartered in Portland, Ore., at 800-723-9166, or visit http://www.psoriasis.org/.

About Amgen

Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit http://www.amgen.com/.

Forward-Looking Statement

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in Amgen's Form 10-K for the year ended December 31, 2005, and in Amgen's periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. In addition, sales of Amgen's products are affected by the availability of reimbursement and the reimbursement policies imposed by third party payors, including governments, private insurance plans and managed care providers, and may be affected by domestic and international trends toward managed care and health care cost containment as well as possible U.S. legislation affecting pharmaceutical pricing and reimbursement. Government regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, Amgen competes with other companies with respect to some of Amgen's marketed products as well as for the discovery and development of new products. Amgen believes that some of the newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Amgen's products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with its products. In addition, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors and there can be no guarantee of Amgen's ability to obtain or maintain patent protection for its products or product candidates. Amgen cannot guarantee that it will be able to produce commercially successful products or maintain the commercial success of its existing products. Amgen's stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of its products or product candidates. Further, the discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include risks associated with the inherent uncertainty of the timing and success of product research, development and commercialization (including with respect to our pipeline products), drug pricing and payment for our products by government and third-party payors, manufacturing, data generated on the safety and efficacy of our products, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, global business operations, product liability and other types of litigation, the impact of legislation and regulatory compliance, intellectual property rights, strategic relationships with third parties, environmental liabilities, and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS." We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Contact: Sonia Fiorenza
Amgen, Inc.